Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cheng-Ta Yang

Showing results (261-270 of 310) with videos related to

Pageof 31
Sort By:
American Journal of Cancer Research|October 11, 2023
Generation and validation of a predictive model for estimating survival among patients with EGFR-mutant non-small cell lung cancerChien-Yu Lin, Yun-Tse Chou, Po-Lan Su, et al.
International Journal of Cancer|September 24, 2021
Afatinib treatment in a large real-world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutationChi-Hsien Huang, Jia-Shiuan Ju, Tzu-Hsuan Chiu, et al.
Clinical Medicine Insights. Oncology|July 8, 2025
Real-World Efficacy and Safety of S-1 Monotherapy in Non-Small Cell Lung Cancer Management: Insights From a Multicenter Retrospective Cohort StudyI-Lin Tsai, Chien-Yu Lin, Po-Lan Su, et al.
Thoracic Cancer|September 28, 2018
Impact of prolonged and early bevacizumab treatment on the overall survival of EGFR-mutant and EGFR-wild type nonsquamous non-small cell lung cancerYu-Chen Huang, Shih-Min Shen, Chien-Ying Liu, et al.
Scientific Reports|November 21, 2023
Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLCJia-Shiuan Ju, Allen Chung-Cheng Huang, Pi-Hung Tung, et al.
Therapeutic Advances in Medical Oncology|January 22, 2024
Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLCPi-Hung Tung, Tzu-Hsuan Chiu, Allen Chung-Cheng Huang, et al.
Therapeutic Advances in Medical Oncology|March 17, 2025
Multivariable model for predicting 5-year survival in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective studyQi-An Wang, I-Lin Tsai, Chien-Yu Lin, et al.
Thoracic Cancer|April 14, 2020
Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancerChia-Hsun Chu, Tzu-Hsuan Chiu, Chin-Chou Wang, et al.
Thoracic Cancer|July 6, 2019
Oral vinorelbine plus cisplatin with concomitant radiotherapy as induction therapy for stage III non-small cell lung cancer: Results of a single-arm prospective cohort studyPing-Chih Hsu, John Wen-Chang Chang, Chun-Chieh Wang, et al.
Biomed Research International|July 26, 2014
Circulating endothelial-derived activated microparticle: a useful biomarker for predicting one-year mortality in patients with advanced non-small cell lung cancerChin-Chou Wang, Chia-Cheng Tseng, Chang-Chun Hsiao, et al.
Pageof 31

Showing results (261-270 of 310) with videos related to

Sort By:
Pageof 31
American Journal of Cancer Research|October 11, 2023
Generation and validation of a predictive model for estimating survival among patients with EGFR-mutant non-small cell lung cancerChien-Yu Lin, Yun-Tse Chou, Po-Lan Su, et al.
International Journal of Cancer|September 24, 2021
Afatinib treatment in a large real-world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutationChi-Hsien Huang, Jia-Shiuan Ju, Tzu-Hsuan Chiu, et al.
Clinical Medicine Insights. Oncology|July 8, 2025
Real-World Efficacy and Safety of S-1 Monotherapy in Non-Small Cell Lung Cancer Management: Insights From a Multicenter Retrospective Cohort StudyI-Lin Tsai, Chien-Yu Lin, Po-Lan Su, et al.
Thoracic Cancer|September 28, 2018
Impact of prolonged and early bevacizumab treatment on the overall survival of EGFR-mutant and EGFR-wild type nonsquamous non-small cell lung cancerYu-Chen Huang, Shih-Min Shen, Chien-Ying Liu, et al.
Scientific Reports|November 21, 2023
Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLCJia-Shiuan Ju, Allen Chung-Cheng Huang, Pi-Hung Tung, et al.
Therapeutic Advances in Medical Oncology|January 22, 2024
Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLCPi-Hung Tung, Tzu-Hsuan Chiu, Allen Chung-Cheng Huang, et al.
Therapeutic Advances in Medical Oncology|March 17, 2025
Multivariable model for predicting 5-year survival in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective studyQi-An Wang, I-Lin Tsai, Chien-Yu Lin, et al.
Thoracic Cancer|April 14, 2020
Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancerChia-Hsun Chu, Tzu-Hsuan Chiu, Chin-Chou Wang, et al.
Thoracic Cancer|July 6, 2019
Oral vinorelbine plus cisplatin with concomitant radiotherapy as induction therapy for stage III non-small cell lung cancer: Results of a single-arm prospective cohort studyPing-Chih Hsu, John Wen-Chang Chang, Chun-Chieh Wang, et al.
Biomed Research International|July 26, 2014
Circulating endothelial-derived activated microparticle: a useful biomarker for predicting one-year mortality in patients with advanced non-small cell lung cancerChin-Chou Wang, Chia-Cheng Tseng, Chang-Chun Hsiao, et al.
Pageof 31